Investors

2018 News

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
Feb 14, 2018CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
SEATTLE, Feb. 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY on Thursday, February 15, 2018 at 2:30 PM ET and host one-on-one meetings. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma Corp. CTI BioPharma Corp. is a biopharm... 
Printer Friendly Version
Feb 13, 2018CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
SEATTLE, Feb. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. ("CTI BioPharma") (NASDAQ: CTIC) today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, the underwriters exercised in full their option to purchase 3,000,000 additional shares of common stock at the public offering price, less the underwriting discount. The expected proceeds to CTI BioPha... 
Printer Friendly Version
Feb 09, 2018CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
SEATTLE, Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPharma has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less the underwriting discount. Proceeds to CTI BioPharma from the offeri... 
Printer Friendly Version
Feb 05, 2018CTI BioPharma Announces Launch of Follow-On Offering
SEATTLE, Feb. 5, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced the launch of a proposed underwritten public offering of shares of its common stock. In addition, CTI BioPharma expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. The Company intends to use the net proceeds of the offering to complete the PAC203 clinical trial, complete the review of the pacritinib MAA by the EMA, conduct additional research c... 
Printer Friendly Version
Jan 25, 2018CTI BioPharma Provides Corporate and European Regulatory Update
- CTI BioPharma reincorporated in State of Delaware, delisted from Borsa Italiana MTA Exchange - Extension granted by CHMP of the EMA for response to Day 120 List of Questions for the MAA for pacritinib SEATTLE, Jan. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that it has been reincorporated in the State of Delaware following a Special Meeting of Shareholders, triggering an automatic delisting of CTI's common stock from the Borsa Italiana M... 
Printer Friendly Version
Jan 18, 2018CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®
SEATTLE, Jan. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it expects to receive a $10 million milestone payment in February, 2018 from Teva Pharmaceutical Industries Ltd.  related to the achievement of a milestone for U.S. Food and Drug Administration approval of TRISENOX® (arsenic trioxide) for first line treatment of acute promyelocytic leukemia. The milestone will be paid pursuant to an acquisition agreement for TRISENOX previously entered into with... 
Printer Friendly Version